dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
  • Home
  • CompanyHeidelberg Pharma AG

June 28, 2022: Heidelberg Pharma AG

Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022

Heidelberg Pharma AG announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:

Please read the whole article here

News 2022

May 9, 2022: Heidelberg Pharma AG

Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure

As of 27th February 2022, Heidelberg Pharma and Huadong Medicine Co., Ltd., Hangzhou, China, (Huadong) have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement regarding an equity investment in Heidelberg Pharma. The investment by Huadong is planned in August 2022 totaling EUR 105 million, representing 35% of outstanding shares after the transaction, consisting of a rights issue and a share transfer.

Please read the whole article here
News 2022

April 28, 2022: Heidelberg Pharma AG

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022

  • Start of clinical trial with HDP-101 in multiple myeloma
  • Financing commitment of up to EUR 36 million obtained from main shareholder dievini
  • Signing of a strategic partnership with Huadong Medicine with an overall volume of up to one billion US dollars
  • Financials in line with planning still without taking into account the partnership with Huadong

Heidelberg Pharma AG today reported on the first three months of fiscal year 2022 (1 December 2021 – 28 February 2022) and the Group’s financial figures.

Please read the whole article here
News 2022

April 7, 2022: Heidelberg Pharma AG

Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022

Heidelberg Pharma AG announced today that it will present preclinical data on its proprietary Amanitin-based ATAC® technology at the American Association for Cancer Research (AACR) 2022 Annual Meeting. The meeting will take place in New Orleans, Louisiana, USA, from 8th – 13th April 2022.

Details of the poster presentation:
Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models

Please read the whole article here

News 2022

March 24, 2022: Heidelberg Pharma AG

Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update

• Start of clinical trial with HDP-101 in multiple myeloma
• Signing of strategic partnership with Huadong Medicine
• Successful financing activities
• Financial figures in line with adjusted forecast
• Conference call to be held on 24 March 2022 at 3:00 p.m. CET

Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2021 (1 December 2020 – 30 November 2021) and its outlook for 2022.

Please read the whole article here
News 2022

March 10, 2022: Heidelberg Pharma AG

Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117

Heidelberg Pharma AG today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the development candidate MGTA-117 in a Phase I/II study. The achievement of this milestone triggered a milestone payment to Heidelberg Pharma.

Please read the whole article here

News 2022

February 28, 2022: Heidelberg Pharma AG

Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment

  • Heidelberg Pharma grants Huadong exclusive license to develop and commercialize HDP-101 and HDP-103 in Asia1 (excluding Japan), plus exclusive opt-in rights for two more pipeline candidates, with a total deal value of up to USD 930 million (EUR 825 million)
  • Huadong will also participate in a rights issue and acquire a percentage of current shareholdings from existing shareholders including dievini2, totaling EUR 105 million
  • Huadong to become second largest shareholder; dievini remains largest shareholder
  • Heidelberg Pharma plans rights issue of up to EUR 80 million at EUR 6.44 per share
  • Conference call on Monday, 28th February 2022 at 01:00 pm CET

Heidelberg Pharma AG and Huadong Medicine Co., Ltd., Hangzhou, China, today announced that the companies have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement. The agreements were concluded with wholly owned subsidiaries of Huadong, one of the leading pharmaceutical companies in China with a focus on oncology and ADC research, development and commercialization.

Please read the whole article here
News 2022

February 17, 2022: Heidelberg Pharma AG

Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini

Heidelberg Pharma AG today announced that it has secured a financing commitment in the amount of up to EUR 36 million from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, (dievini). This commitment replaces the not yet fully used financing commitment from March 2021.
The detailed form of the financing will be decided by the management and supervisory boards of Heidelberg Pharma as well as dievini at a later date.
The financing commitment will enable Heidelberg Pharma to advance its business activities, in particular to completely conduct the clinical Phase I/IIa with HDP-101 and to further develop the candidates HDP-102 und HDP-103, if and to the extent that this is not achieved through potential alternative capital measures. Based on the current planning, the Company’s cash reach is secured until mid-2023.

Please read the whole article here
News 2022

October 28, 2021: Heidelberg Pharma AG

Heidelberg Pharma Participates at Various Conferences

Heidelberg Pharma AG will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies that, when coupled to an antibody, can specifically kill even dormant cancer cells and overcome resistance. The first product candidate, HDP-101, is in clinical development for the treatment of multiple myeloma.

Please read the whole article here

News 2021

October 7, 2021: Heidelberg Pharma AG

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021

  • Paul-Ehrlich-Institut follows the FDA in giving clearance to begin a Phase I/IIa trial of HDP-101; first trial centers initiated in the USA
  • Gross issue proceeds of over EUR 20 million generated from private placement in June
  • Significant advances made in partner projects
  • Guidance revised

Heidelberg Pharma AG today reported on the first nine months of fiscal year 2021 (1 December 2020 – 31 August 2021) and the Group’s financial figures.

Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “We are delighted to have achieved important milestones in recent weeks and to have cleared several organizational hurdles for our initial clinical trial of HDP-101. The first two trial centers were initiated recently, and we are now eagerly awaiting the inclusion of the first patient.

Please read the whole article here

News 2021
Older Entries
  • News 2022
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • General
  • Company
    • AC Immune SA
    • Apogenix AG
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz